News
-
-
-
REGULATED PRESS RELEASE
Biophytis entre en négociation exclusive avec une société pharmaceutique chinoise pour licencier BIO101
Biophytis entre en négociation exclusive avec une société pharmaceutique chinoise pour licencier BIO101. L'objectif est de co-développer et commercialiser le traitement en Chine -
REGULATED PRESS RELEASE
Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101
Biophytis enters exclusive negotiations with a Chinese pharmaceutical company to license BIO101 for viral respiratory infections, sarcopenia, and obesity. The potential partnership aims to develop and commercialize the drug in China's growing pharmaceutical market -
-
PRESS RELEASE
Helvetica Swiss Opportunity Fund a été ouvert aux investisseurs publics et fera son entrée en Bourse en février 2025, en vue de la fusion avec le HSC Fund
Le Helvetica Swiss Opportunity Fund s'ouvre aux investisseurs publics et sera coté en Bourse en février 2025, en vue de sa fusion avec le HSC Fund. Communiqué de presse du 14.01.2025 -
PRESS RELEASE
Helvetica Swiss Opportunity Fund now open to public investors and due to be listed on the stock exchange in February 2025, with a view to merging with the HSC Fund
Helvetica Swiss Opportunity Fund, approved by FINMA, to be listed on SIX Swiss Exchange on 11 February 2025. Merger with HSC Fund to follow. Fund offers value through stable real estate assets -
PRESS RELEASE
Southern Cross Gold Consolidated Completes Spin-Out, Consolidation and Name Change, To Commence Trading on the ASX
Southern Cross Gold Consolidated Ltd completed spin out of uranium assets with SUA Holdings Limited. Consolidation of common shares, name change, and new ticker symbol 'SXGC'. Listing on ASX -
-